ViRAZE is an emerging biotechnology company utilizing a patented high throughput screening technology to discover and develop small molecules with antiviral activity to treat viral diseases. Our initial emphasis is to develop the first approved drug to treat the viral dermatology disease, Molluscum contagiosum, which affects 3 to 4 million children in the US per year. Viraze was spun out of the University of Pennsylvania in 2015 through the PCI Ventures UPstart Company Incubator. The company is located in Philadelphia, PA.
Rajiv Khosla, PhD
Chief Executive Officer
Dr. Khosla is an accomplished business executive with over 25 years of success in pharmaceuticals, biotech, and medical devices. His career includes Board, C-Suite, and VP Business & Corporate Development positions, as well as a proficiency in international business from having lived and worked in the US, Europe, and Asia. Dr. Khosla recent roles include: CEO/CSO/Board at IntelGenx Corp., CEO/Board at Orasi Medical, and Vice President Business Development at Biovail Pharmaceuticals, Inc., where he successfully led and concluded several specialty CNS transactions in neurology and psychiatry. Dr. Khosla has a Ph.D. in pharmaceutical science and a Bachelor of Pharmacy from the University of Nottingham (UK), an MBA from Henley Management College (UK), and is a registered pharmacist (UK).
Dr. Ricciardi is Professor and Chair of Microbiology at the School of Dental Medicine and Professor and Member of the Abramson Cancer Center at the University of Pennsylvania. Dr. Ricciardi is credited with developing one of the first, widely used DNA technologies for mapping hundreds of genes by identifying the proteins they encode. Among a long list of scientific accomplishments, Dr. Ricciardi is known for having discovered the first transcriptional activator that up-regulates expression of cellular genes, and the discovery of a key mechanism that modulates the Master Regulator (NF-kB) of the immune system.
Dr. Ricciardi has served as a consultant to Children’s Hospital of Philadelphia (CHOP), Smith Kline Pharmaceuticals, the NIH, was awarded a NATO Visiting Professorship at Ferrara Medical School and has been a speaker at numerous international scientific meetings and universities. He has authored over 100 publications and is inventor on issued patents on antiviral therapeutics and on recombinant delivery vectors for use as vaccines and gene therapy. He received his Ph.D. from the University Illinois, Urbana and was an NIH and Charles King Fellow in the Department of Biological Chemistry at Harvard Medical School.
Head of Operations
Mr. Han is the Head of Operations at Viraze. He has over 20 years of experience in Strategic Marketing, Brand Marketing, Product Commercialization and New Product Development. Prior to joining Viraze, Mr. Han was Vice President of Dermatology Marketing at Valeant, were he was part of the leadership team that grew the dermatology business from $250 million to $1 billion in sales. This included the acquisition and integration of two leading dermatology companies, Ortho Derm and Dermik, as well as the development of various dermatology compounds and assets. Prior to Valeant, Mr. Han was Vice President at Biovail where he successfully provided strategic commercial leadership, forecasting, market research and deal modeling for over 10 acquisitions, valued at more than $2.5 billion. Mr. Han started his pharmaceutical career at Bristol-Myers Squibb, moving into leadership roles at both Novartis and Schering Plough. Mr. Han has a BA from Binghamton University in NY.